Gil Beyen – Chief Executive Officer
Gil Beyen is Chief Executive Officer of ERYTECH Pharma since May 2013 and President of ERYTECH Pharma Inc. since 2016. He served as ERYTECH’s Chairman of the Board from August 2012 until June 2019. Between 2000 and 2013, Mr. Beyen was Chief Executive Officer and Director of TiGenix (Euronext: TIG), a company he co-founded. He previously served as the head of the Life Sciences division of Arthur D. Little, an international management consulting firm, in Brussels. Mr. Beyen holds a MSc in Bioengineering from the University of Leuven (Belgium) and an M.B.A. from the University of Chicago.
Eric Soyer – Chief Financial Officer & Chief Operating Officer
Eric joined Erytech in 2015. Eric Soyer has a more than 20 year experience in Management positions in financial and operational fields in public or private companies including eight years as Chief Financial Officer of EDAP TMS S.A., and Managing Director of the French affiliate Chief Financial Officer for a company operating nursing homes and post-care clinics, Financial and legal director for an insurance services company. He started his career as a financial controller and cost accountant for Michelin Group. Eric Soyer graduated from the ESC Clermont School of Management (France) and holds an M.B.A. from the University of Kansas and an Executive M.B.A. from the HEC Paris School of Management (France).
Iman El-Hariry, MD, PhD – Chief Medical Officer
Iman El-Hariry, M.D., Ph.D. has served as our Chief Medical Officer and employee of our wholly-owned U.S. subsidiary, ERYTECH Pharma, Inc., since June 2015. Prior to her appointment as Chief Medical Officer, she served as President of Azure Oncology Consulting from July 2014 to June 2015 and also assisted us in a consulting role from November 2014 to June 2015. Dr. El-Hariry served as Vice President of Clinical Research at Synta Pharmaceuticals from November 2010 to July 2014 and as Global Head of Oncology at Astellas Pharma, Inc. from June 2009 to July 2010. From 2001 to 2009, she served as Director of Clinical Development, Oncology at Glaxo Smith Kline. Dr. El-Hariry is a licensed oncologist with an M.D. from Alexandria Medical School (Egypt) and a Ph.D. in Cancer Research from Imperial College of Science and Medicine (United Kingdom).
Jean-Sébastien (JS) Cleiftie, MS, MBA – Chief Business Officer
JS has been our Chief Business Officer since October 2016. He brings 15 years of experience in drug development, life science venture capital, and business development and licensing within the U.S. and European biopharmaceutical ecosystems. Prior to his appointment he served as Associate Vice-President, Global Business Development & Licensing at Sanofi in Paris, France, where he led licensing transactions across multiple therapeutic areas, financial valuation activities, and other strategic projects. Prior to joining Sanofi, JS was a Principal at Innoven Partners, a venture capital firm active as lead investor in healthcare and IT in Europe and the U.S. He was responsible for healthcare investment opportunity assessment, transaction execution, and active portfolio management, and led equity investments in a number of biotech and medtech companies which achieved successful exits. He started his career in drug development in the U.S. as a research scientist with Aventis (now Sanofi) in the fields of immunotherapy and gene therapy for cancer. JS earned a M.S. in Biological & Medical Sciences and a M.S. in Immunology from the University of Paris V, and received his M.B.A from Cornell University.
Jérôme Bailly, Pharm.D. – Chief Quality Officer, Deputy General Manager and Qualified Person
Jérôme Bailly, Pharm.D. has served as our Qualified Person since December 2011, and has served as our Director of Pharmaceutical Operations since 2007. Prior to 2007, he was the Director of QA/Production at Skyepharma and Laboratoire Aguettant. Dr. Bailly holds a Pharm.D. and a degree in Chemica Engineering, specializing in Biopharmaceutical Engineering and Cellular Production from École Polytechnique de Montréal (Canada).
Françoise Horand, MSc – Director of Research and Development Operations
Françoise joined Erytech in 2008. With 10 years’ experience in toxicology and preclinical drug regulations obtained at MDS Pharma Services (now Charles River Laboratories), she was involved in putting together the R&D team when it started and launching the laboratory. She currently heads up the teams in charge of research projects as well as the research laboratory.
Françoise holds a Master’s degree in Biochemistry from the University of Lyon, and is also a graduate of the Ecole Pratique des Hautes Etudes in immunology.
Anne-Cécile Fumey – Human Resources Director
Anne-Cécile Fumey was appointed Human Resources Director at Erytech Pharma in February 2016. Prior to joining the company, Mrs. Fumey served within several high-growth blue-chip companies. She was International HR Director with Clasquin Group and Senior HR Manager at National Bank of Canada in Montréal. Anne-Cécile Fumey started her career with BD where she was responsible for Human Resources management at the European headquarters, then within the Pharmaceutical Systems business unit, before being appointed Compensation and Benefits Manager France.
Mrs. Fumey graduated from the Grenoble Institute of Political Studies (IEP) and has a postgraduate degree (DESS) in Human Resources Management from the Grenoble Graduate School of Management (IAE).
Brian Schwab – VP, Legal Affairs & General Counsel
Brian Schwab joined ERYTECH Pharma in January 2020 as VP, Legal Affairs & General Counsel and has over 25 years of French and US in-house and law firm experience. Prior to his appointment, he served as General Counsel to two Global Business Units at Solvay in Lyon and as Chief Licensing Officer and General Counsel at Scynexis, in North Carolina. He previously served as Deputy General Counsel at Aventis CropScience and as Senior Legal Counsel at Rhone-Poulenc. Mr. Schwab also worked as an attorney for Freshfields Bruckhaus Deringer in Paris and for Cooley LLP in Palo Alto, California. Mr. Schwab received a B.A. from Cornell University, a law degree from the University of California – Los Angeles and a LLM degree from the University of Maastricht in the Netherlands.
Stewart Craig – Chief Technical Officer
Dr. Stewart Craig joined ERYTECH in 2020. For the past 25 years, Dr. Craig has held executive level positions designing, implementing and operating the CMC and GMP manufacturing infrastructure for various pioneering cell and gene therapy companies worldwide, including as Chief Manufacturing Officer of Orchard Therapeutics, SVP Technical Operations of Sangamo, EVP Manufacturing & Regulatory at Stemcells Inc., Chief Technology Officer at PCT Cell Therapy Services and Chief Operating Officer at Xcyte Therapies. Stewart also has extensive experience in the successful management of regulatory affairs for cell and gene therapy submissions in the US, Canada and Europe.
Stewart holds a B.Sc. in Biochemistry and a Ph.D. in Physical Biochemistry from Newcastle University (U.K.).